In this episode, Sacha Hebbert sits with the CEO, Benjamin Lightburn of Filament Health, to discuss the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
Similar Posts
The Awakening of Consciousness Conference with Paul Karasik
In this episode, Matthew and Paul discuss The Psychedelic Institute’s aspirations with the launch of the Awakening of Consciousness Conference, the differences between legalization and decriminalization, and the importance of being brave, and thinking outside the box in understanding what it takes to make the most of one’s own experience of sacred plant medicines.
Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
Psychedelic Business Spotlight: June 11, 2021
This week in psychedelic business news: An all-female biotech company, psychedelic-assisted psychotherapy for COVID front-liners, and more.
Interview With Dr. Joseph Tucker
MagicMed Industries’ CEO, Dr. Joseph Tucker, talks about their psychedelic library, the company’s plans to go public and what the future of psychedelic research looks like.
Hawaii Moves to Legalize Psilocybin Treatment
Hawaii may soon be more than just Paradise. It may also be a psychedelic therapy hub. A new state measure aims to legalize psilocybin, the hallucinogenic compound in certain mushrooms.
Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)
What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.
MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF